Supplementary Table S1: Key alterations in pathway components from Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors
Year: 2023
Type: supplementary-materials
Abstract: Key alterations in cyclin-CDK4/6-p16-Rb pathway components across tumor types.
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361920220